Please assess the completion status of the following clinical trial:

Trial Title: Ezetimibe in Patients Hypo-responsive to Statins

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients will need to have an LDL-C level of 130 mg/dl or greater without treatment.~* They must have demonstrated an initial LDL-C reduction of less than 25% on 10 mg of atorvastatin or 20 mg of simvastatin.~* Eligible patients will be those deemed by their physicians to be eligible for lipid lowering therapy with a statin and to have stable CAD, CAD equivalent per NCEP guidelines, or Framingham risk of 10-20%.~Exclusion Criteria:~* Recent (\<3 months) diagnosis of Acute Coronary Syndromes due to ethical considerations \[10\].~* Pregnant patients, those planning to become pregnant, or those who are breast feeding, those with liver disease, history allergic reaction to any agent used in the trial, history of myositis, myopathy, pancreatitis, hypertriglyceridemia (TG \> 400 mg/dL), history of significant alcohol or drug abuse, history of organ transplantation, or patient refusal.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Atorvastatin (Type: PLACEBO_COMPARATOR): None
- Atorvastatin/Ezetimibe (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).